Feasibility of Redo-Transcatheter Aortic Valve Replacement in Sapien Valves Based on In Vivo Computed Tomography Assessment
- 1 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (11) , e013497
Abstract
BACKGROUND: Our aim was to assess the feasibility of repeat transcatheter aortic valve (TAV) replacement for degenerated Sapien3 (S3) prostheses by simulating subsequent implantation of S3 or Evolut, using in vivo computed tomography–based sizing and the impact on coronary and patient-prosthesis mismatch risks. METHODS: Computed tomography scans from 356 patients with prior S3 TAV replacement implantation were analyzed. The in vivo sizing for second TAV based on averaged area of 3 levels of outflow, mid (narrowest) and inflow, was compared with in vitro recommendations, that is, same size as index S3 for second S3 and 1 size larger for Evolut. Risks of coronary obstruction and patient-prosthesis mismatch were determined by valve-to-aorta distance and estimated effective orifice area, respectively. RESULTS: Overall, the majority of patients (n=328; 92.1%) had underexpanded index S3 with an expansion area of 94% (91%–97%), leading to significant differences in size selection of the second TAV between in vivo and in vitro sizing strategies. Expansion area P P <0.001) and selecting Evolut as the second TAV (11% risk reduction in intermediate- or high-risk patients) reduced coronary risk. Estimated moderate or severe patient-prosthesis mismatch risk was 21% for S3-in-S3 and 1% for Evolut-in-S3, assuming optimal expansion of the second TAV. CONCLUSIONS: Redo-TAV replacement with S3-in-S3 and Evolut-in-S3 could be feasible with low risk to coronaries in ≈60% of patients, while the remaining 40% will be at intermediate or high risk. The feasibility of redo-TAV replacement is influenced by sizing strategy, type of second TAV, native annular anatomy, and implant depth.Keywords
This publication has 21 references indexed in Scilit:
- Repeat transcatheter aortic valve implantation and implications for transcatheter heart valve performance: insights from bench testingEuroIntervention, 2021
- Leaflet and Neoskirt Height in Transcatheter Heart ValvesJACC: Cardiovascular Interventions, 2021
- Systematic Approach to High Implantation of SAPIEN-3 Valve Achieves a Lower Rate of Conduction Abnormalities Including Pacemaker ImplantationCirculation: Cardiovascular Interventions, 2021
- Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve BioprosthesesJACC, 2021
- Risk of Coronary Obstruction Due to Sinus Sequestration in Redo Transcatheter Aortic Valve ReplacementJACC: Cardiovascular Interventions, 2020
- Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed TomographyJACC: Cardiovascular Interventions, 2020
- Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis DysfunctionJACC, 2020
- TAVR RouletteJACC: Cardiovascular Interventions, 2020
- Imaging for Predicting and Assessing Prosthesis-Patient Mismatch After Aortic Valve ReplacementJACC: Cardiovascular Imaging, 2019
- Comprehensive Echocardiographic Assessment of Normal Transcatheter Valve FunctionJACC: Cardiovascular Imaging, 2019